January 2nd, 2025 (Shanghai) — We are glad to announce that Marti Dalmases, the Chief Executive Officer of Ahead Therapeutics, will be presenting at the ACCESS CHINA Partnering Forum @ JPM on January 7th-9th, and 21st-23rd, 2025. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the Western biopharma industry.
About Ahead Therapeutics
Ahead Therapeutics is a biotech company dedicated to pioneering a pharmacological platform to treat and cure autoimmune diseases.
In short, we have a proprietary Nano-Platform to Re-Establish Immune Tolerance Against Self-Tissues to Treat and cure Immune Disorders. We are currently in open conversations with some big pharma companies to establish collaboration programs or early out-licensing for some of the assets. At the same time, we are free to talk with FOs / VCs for the next financing round.
The concept is known as “antigen-specific immune tolerance”. We achieve it by mimicking a physiological process for peripheral tolerance generation (the Engulfment of the Apoptotic Cells by DCs), using a “Synthetic Product” (PS-Liposomes-encapsulating Ag) that contains only mammals self compounds (PS, PC, Cholesterol & Ag). We stop the attack on self-tissue and, consequently, treat and cure the illness. Inside the liposomes, we capsulate the specific antigen responsible for auto-immune response generation, which differs in each disease. Thus, the platform can treat different auto-immune diseases depending on the antigen capsulated inside the liposomes.
We are at the final pre-clinical stage of different assets: Type 1 Diabetes and Multiple Sclerosis. In both animal models (NOD and EAE), the results were excellent, and they proved the disease can be reversed. Moreover, we are in the proof of concept stage for five additional indications: Celiac Disease, Rheumatoid Arthritis, Myasthenia Gravis, Myositis, and Neuromyelitis Optica.
After achieving the aforementioned results, in the period 2023/25 Ahead Therapeutics partnered with Recipharm, a Swedish CDMO, to carry out the advanced scale-up synthesis of the liposome technology and advance through the pre-clinical regulatory phase to reach IND from Regulatory Agencies to initiate the first clinical trials (phase Ib) with humans suffering auto-immune diseases (Proof of Concept / First in Human).
The innovation emerged from prestigious institutions in Spain: Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), the Institut Català de Nano Ciència i Nano Tecnologia de Catalunya (ICN2) www.icn2.cat/en/, and ICREA.
The industrial rights of the patent (PCT = WO2015107240) protecting the technological platform have been fully transferred to Ahead Therapeutics. The Company has raised to date > USD 12 M.
About the speaker
Degree and a doctorate in Medicine from the Universitat Autònoma de Barcelona, an MBA from UAB, a Master’s in Scientific Communication from Pompeu Fabra University, and a Master’s in Hyperbaric Medicine from the University of Barcelona. Dr. Martí Dalmases has worked in the management of research and innovation projects, primarily at the Parc Taulí Health Corporation in Sabadell. He has been involved in the creation of technology-based biotech companies and has experience in other sectors. He has extensive experience in creating technology-based companies, technology transfer, and serves on the Board of Directors.
About ACCESS CHINA Partnering Forum
ACCESS CHINA Partnering Forum @ JPM is scheduled to be held on January 7th-9th, and 21st-23rd, 2025, via Zoom webinar. This event helps biotechs/pharmas efficiently present their assets in front of 500+ healthcare companies and VCs online. During the event, the audience can have access to innovative pharma and healthcare products from worldwide.
Conference Name: ACCESS CHINA Partnering Forum
Date & Time: January 7-9 (Live), and 21-23(VoD), 2025, China time
Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception
Scale: Expected 500+ participants Online; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs
View more information at https://biotochina.org/
Contact us:
To register for ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact:
Wendi Xiang
BioToChina.org 